the ADBL report

Issue #119, March 2021

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 19, 2021. The Committee reviewed Manufacturer submissions for twenty-seven (27) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a supplementary assessment of the coverage status of one (1) Drug Product.

In addition to Drug Products reviewed by the Expert Committee, twenty-seven (27) Drug Products underwent Expedited Review for listing on the *ADBL* effective March 1, 2021.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective March 1, 2021:

- **ONPATTRO* 2 mg/mL vial injection** (patisiran sodium) (ANT) via Special Authorization (SA)
- **TRINTELLIX 5 mg, 10 mg, 15 mg & 20 mg tablets** (vortioxetine hydrobromide) (LBC)
- **TEGSEDI* 284 mg/1.5 mL injection syringe** (inotersen sodium) (AKC) via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (03/2021)

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2021:

- **AVSOLA* 100 mg/vial injection** (infliximab) (AMG) via SA for the indications of Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease and Fistulizing Crohn's Disease, Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), and Ulcerative Colitis
- **BRENZYS* 50 mg/mL auto injector syringe & injection syringe** (etanercept) (SSB) via SA for the indications of PsO, Polyarticular Juvenile Idiopathic Arthritis (pJIA) and PsA
- **TRUXIMA* 10 mg/mL (10 mL & 50 mL) injections** (rituximab) (CTC) via SA for the indications of Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective March 1, 2021:

- **TARO-CIPROFLOXACIN/DEXAMETHASONE 0.3/0.1% otic suspension** (ciprofloxacin hydrochloride/ dexamethasone) (TAR)
- **TEVA-LIOTHYRONINE 5 mcg & 25 mcg tablets** (liothyronine sodium) (TEV)

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2021:

- **HUMIRA* 20 mg/0.2 mL injection syringe** (adalimumab) (ABV) via SA for the indication of pJIA

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective March 1, 2021:

- **ENBREL* 25 mg/vial injection & 50 mg/mL injection syringe** (etanercept) (AMG) for the indications of PsO and pJIA
- **ERELZI* 25 mg/0.5 mL injection syringe and 50 mg/mL injection syringe & sensoready auto injector** (etanercept) (SDZ) for the indications of PsO and pJIA
- **MAVIRET* 40 mg/100 mg tablet** (pibrentasvir/ glecaprevir) (ABV)
- **RUXIENCE* 10 mg/mL injection** (rituximab) (PFI) for the indication of GPA/MPA
- **SOVALDI* 400 mg tablet** (sofosbuvir) (GIL)

Due to the Biosimilar Initiative, the following Drug Product has been delisted effective March 1, 2021:

- **RITUXAN* 10 mg/mL injection** (rituximab) (HLR)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (03/2021)